• Other
  • Exited

EKR Therapeutics Inc. is a specialty pharmaceutical company focused on identifying, fostering and targeting the growth of products to serve the needs of the acute-care hospital setting. EKR’s products include CARDENE® I.V. for short-term treatment of hypertension and RETAVASE® for management of various AMI related conditions. EKR was acquired by Cornerstone Therapeutics, Inc. in June 2012 for $125 million plus up to an additional $25 million in milestone payments.